Diagnosis of ascites in infants and children by history, examination and investigations

Ascites

Diagnosis of Ascites in Infants and Children

Diagnosis of ascites in infants and children fromega age of 1month to 18 year

Asmaa abo bakr Ahmed

Doctor

Assiut University

P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.

EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.
IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.

Lymphoma, Extranodal NK-T-Cell

gemcitabine :1250mg/m2 (ivdrip) on days 1

Gemcitabine

Oxaliplatin

pegaspargase : 2500 IU/m2 (intramuscular injection)

Pegaspargase

50 mg/m 2 /day 24 h continuous infusion on days 1-4

Etoposide

0.4 mg/m 2 /day 24 h continuous infusion on days 1-4

Vincristine

10 mg/m 2 /day 24 h continuous infusion on days 1-4

Doxorubicin

cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5

Cyclophosphamide

60 mg/m 2 /day 60 mg/m 2 /day on days 1-5

Prednisone

IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.

IMRT

Sun Yat-sen University Cancer Center

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study

time from the date of enrollment to date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first

The criteria for the efficacy evaluation (overall response rate and complete remission) of the regimen is according to the following article:
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.

overall survival (OS): time from the date of enrollment to date of death from any cause, or date of lost follow-up, whichever comes first

including hematological safety and non-hematological safety.All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

wanghua

Professor of departments of Department of Hematological Oncology, Sun Yat-sen University Cancer Center.

Sun Yat-sen University

GELOX:
gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
IFRT
IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
the first cycle of chemotherapy was initiated on the same day of radiotherapy.

gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days

GELOX

IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions

IFRT

Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China,

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) With Concurrent Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma:a Phase II Study

1.The criteria for the efficacy evaluation (overall response rate and complete remission) of the regimen is according to the following article.
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.

progression free survival(PFS): time from the date of enrollment to date of disease progression, or death of any cause, or date of lost follow-up, whichever comes first

overall survival (OS): time from the date of enrollment to date of death from any cause, or date of lost follow-up, whichever comes first.

Xia Zhongjun

Professor

Blood, throat swab, nasopharyngeal aspiration, and rectal swab will be obtained during acute illness and at convalescence (about 2 weeks after discharge). These specimens will be processed for viral isolation, bacterial culture and toxin detection, PCR, subtractive cloning, VIDISCA, gene chips, peptide library, cytokine/chemokine measurement, antibody detection for specific pathogens, etc. Questionnaire for contact history and clinical symptoms will be performed.

Kawasaki Disease

National Taiwan University Hospital

Etiology Study of Kawasaki Disease

Etiology Study of Kawasaki Disease--A Prospective Household and Case Control Study

The mean age of the 226 KD cases was 2.07 years, and the male to female ratio was 1.43 (133 boys to 93 girls). Their mean fever duration was 7.5 days with a mean peak temperature of 39.7°C. In addition to the typical symptoms of fever, neck lymphadenopathy, lip fissure and/or strawberry tongue, skin rash, nonpurulent bulbar conjunctivitis, palm/sole erythema, and induration followed by periungual desquamation, these KD cases also exhibited cough (69%), rhinorrhea (58%), and diarrhea (45%). Cases of KD had a significantly higher positive rate of viral isolation in comparison with the control group (7.5% vs. 2.2%, p = 0.02). Compared with the control group, cases of KD were more likely to have overall positive rates of viral PCR (50.4% vs. 16.4%, p < 0.001) and for various viruses including enterovirus (16.8% vs. 4.4%, p < 0.001), adenovirus (8.0% vs. 1.8%, p = 0.007), human rhinovirus (26.5% vs. 9.7%, p < 0.001), and coronavirus (7.1% vs. 0.9%, p = 0.003).

globulin/karijes

Diagnosis of Ascites in Infants and Children

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Etiology Study of Kawasaki Disease

Najkompletnija baza ljekovitog bilja potpomognuta naukom